# US 2010/0168448 A1 · Methods of Preparing Cannabinoids From Plant Material

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168448 A1
- Document ID: US20100168448A1
- Status: Published application
- Kind: A1
- Application number: 12/714,907
- Filed: 2010-03-01
- Published: 2010-07-01
- Earliest claimed: 2002-09-23
- Assignees: GW Pharma Limited
- Inventors: Ian Flockhart; Gary William Wheatley; Su Dring; Leslie Archer
- Web page: https://patentgrep.com/patent/US20100168448A1

## CPC

- B01D 11/0288: {Applications, solvents}
- C07C 65/19: having unsaturation outside the aromatic ring
- A61P 1/08: for nausea, cinetosis or vertigo; Antiemetics
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/06: Antimigraine agents
- A61P 25/22: Anxiolytics
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07D 311/80: Dibenzopyrans; Hydrogenated dibenzopyrans
- C07C 2601/16: the ring being unsaturated
- Y10T 436/25375: Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]
- B01D: SEPARATION (separating solids from solids by wet methods B03B, B03D; by pneumatic jigs or tables B03B; by other dry methods B07; magnetic or electrostatic separation of solid materials from solid materials or fluids, separation by high-voltage electric fields B03C; centrifuges, vortex apparatus B04; presses per se for squeezing-out liquid from liquid-containing material B30B9/02; treatment of water C02F, e.g. softening by ion-exchange C02F1/42; {arrangements of air intake cleaners in gas turbine plants F02C7/05} ; arrangements or mounting of filters in air-conditioning, air-humidification or ventilation F24F13/28)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

The invention relates to methods of preparing cannabinoids in substantially pure form starting from plant material. Also described are substantially pure preparations of various cannabinoids and cannabinoid acids, and also extracts enriched in cannabinoids and cannabinoid acids.

## Claims

### Claim 1

A method of obtaining a substantially pure cannabinoid or cannabinoid acid or a product enriched in a given cannabinoid or cannabinoid acid from a plant material, comprising:
i) obtaining an extract containing a cannabinoid or cannabinoid acid from a plant material;
ii) subjecting the extract of step (i) to a chromatographic step to produce a partially purified extract;
iii) dissolving the partially purified extract in a first solvent, removing any insoluble material therefrom and removing the solvent; and
iv) dissolving the product obtained in step iii) in a second solvent, removing any insoluble material therefrom, and removing the solvent to obtain the substantially pure cannabinoid or cannabinoid acid or the product enriched in a given cannabinoid or cannabinoid acid, wherein the first and second solvents are different, and wherein one of the first or second solvents is a solvent which is substantially more polar than the cannabinoid/cannabinoid acid which it is desired to purify, and the other solvent is a solvent which is substantially less polar than the cannabinoid/cannabinoid acid which it is desired to purify.

### Claim 2 (depends on 1)

A method according to claim 1 wherein one of the solvents is an alcohol.

### Claim 3 (depends on 2)

A method according to claim 2 wherein one of the solvents is methanol.

### Claim 4 (depends on 1, 2, 3)

A method according to any one of claims 1 to 3 wherein one of the solvents is a straight or branched chain C5-C12 alkane.

### Claim 5 (depends on 4)

A method according to claim 4 wherein one of the solvents is pentane.

### Claim 6 (depends on 5)

A method according to claim 5 wherein one of the solvents is pentane and the other solvent is methanol.

### Claim 7

A method according to any one of the preceding claims wherein the extract containing a cannabinoid or cannabinoid acid obtained in step (i) is prepared by a process comprising solvent extraction of the plant material.

### Claim 8 (depends on 7)

A method according to claim 7 wherein step (i) comprises dissolving the plant material in an extraction solvent, removing any insoluble material from the resultant solution and removing the solvent to form an extract containing a cannabinoid or cannabinoid acid.

### Claim 9 (depends on 7, 8)

A method according to claim 7 or claim 8 wherein the extraction solvent is a non-polar solvent, ethanol, methanol or carbon dioxide.

### Claim 10 (depends on 9)

A method according to claim 9 wherein the non-polar solvent comprises a straight or branched chain C5-C12 alkane.

### Claim 11 (depends on 10)

A method according to claim 10 wherein the non-polar solvent is hexane.

### Claim 12 (depends on 7, 8)

A method according to claim 7 or claim 8, wherein the extraction solvent is acidified.

### Claim 13 (depends on 12)

A method according to claim 12 wherein the extraction solvent is an acidified non-polar solvent.

### Claim 14 (depends on 13)

A method according to claim 13 wherein the extraction solvent is an acidified straight or branched chain C5-C12 alkane.

### Claim 15 (depends on 14)

A method according to claim 14 wherein the extraction solvent is 0.1% v/v acetic acid in hexane.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

A method according to any one of claims 1 to 15, which includes a further step, prior to step (i), of decarboxylating the plant material.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6)

A method according to any one of claims 1 to 6 wherein the extract containing a cannabinoid or cannabinoid acid obtained in step (i) comprises a botanical drug substance derived from the plant material.

### Claim 18 (depends on 17)

A method according to claim 17 wherein the botanical drug substance is prepared by a process comprising solvent extraction of the plant material.

### Claim 19 (depends on 18)

A method according to claim 18 wherein the botanical drug substance is prepared by extraction with carbon dioxide.

### Claim 20 (depends on 19)

A method according to claim 19 wherein the botanical drug substance is prepared by a process comprising extraction with carbon dioxide (CO2), followed by a secondary extraction step to remove a proportion of the non-target materials.

### Claim 21 (depends on 20)

A method according to claim 20 wherein the secondary extraction step is ethanolic precipitation.

### Claim 22 (depends on 20, 21)

A method according to claim 20 or claim 21 wherein the process for preparing the botanical drug substance further includes a charcoal clean-up step.

### Claim 23 (depends on 22)

A method according to claim 22 wherein the botanical drug substance is prepared by a process comprising:
i) optional decarboxylation of the plant material,
ii) extraction with liquid CO2, to produce a crude botanical drug substance,
iii) precipitation with C1-C5 alcohol to reduce the proportion of non-target materials,
iv) removal of the precipitate,
v) treatment with activated charcoal, and
vi) evaporation to remove C1-C5 alcohol and water, thereby producing a final botanical drug substance.

### Claim 24

A method according to any one of the preceding claims wherein the chromatographic step comprises column chromatography.

### Claim 25

A method according to any one of the preceding claims wherein the chromatographic step is based on molecular sizing and polarity.

### Claim 26 (depends on 25)

A method according to claim 25 wherein the chromatographic step is carried out using a Sephadex™ LH-20 matrix.

### Claim 27 (depends on 26)

A method according to claim 26 wherein the chromatographic step is carried out using a 2:1 mixture of chloroform/dichloromethane as solvent.

### Claim 28

A substantially pure preparation of Δ9 tetrahydrocannabinolic acid (Δ9 THCA) having a chromatographic purity of greater than 95%, more preferably greater than 96%, more preferably greater than 97% or most preferably greater than 98% by area normalisation of an HPLC profile.

### Claim 29 (depends on 28)

A preparation according to claim 28 which is a pale yellow crystalline solid at room temperature.

### Claim 30 (depends on 28, 29)

A preparation according to claim 28 or claim 29 which comprises less than 2%, preferably less than 1.5%, most preferably 1% or less Δ9 THC (w/w).

### Claim 31 (depends on 28, 29, 30)

A preparation according to any one of claims 28 to 30 which comprises less than 2%, more preferably less than 1.5%, more preferably less than 1% or most preferably less than 0.5% CBD (w/w).

### Claim 32 (depends on 28, 29, 30, 31)

A preparation according to any one of claims 28 to 31 which comprises less than 2%, more preferably less than 1.5%, or most preferably less than 1% CBN (w/w).

### Claim 33 (depends on 28, 29, 30, 31, 32)

A preparation according to any one of claims 28 to 32 which is obtainable from cannabis plant material using a method comprising:
i) preparing an extract of the cannabis plant material with 0.1% v/v acetic acid in hexane,
ii) filtering the resultant extract and removing solvent from filtrate by rotary evaporation to form an extract enriched in Δ9 THCA,
iii) passing a solution of the resulting Δ9 THCA enriched extract through a column packed with Sephadex-LH20™, eluting with 2:1 chloroform/dichloromethane,
iv) collecting Δ9 THCA rich fractions eluted from the column and removing solvent by rotary evaporation,
v) re-dissolving the crude Δ9 THCA obtained in step iv) in methanol, removing insoluble residue by filtration and removing solvent from filtrate by rotary evaporation,
vi) re-dissolving the product of step v) in pentane, removing insoluble residue by filtration and removing solvent from filtrate by rotary evaporation to produce Δ9 THCA crystals.

### Claim 34

A substantially pure preparation of Δ9 tetrahydrocannabinolic acid (Δ9 THCA) substantially as described herein and having an HPLC profile substantially as shown in FIG. 2.

### Claim 35

A substantially pure preparation of cannabidiolic acid (CBDA) having a chromatographic purity of greater than 90%, more preferably greater than 92% or most preferably greater than 94% by area normalisation of an HPLC profile.

### Claim 36 (depends on 35)

A preparation according to claim 35 which is a pale yellow crystalline solid at room temperature.

### Claim 37 (depends on 35, 36)

A preparation according to claim 35 or claim 36 comprising 5% or less, preferably 4.5% or less, more preferably 4% or less, more preferably 3.5% or less or most preferably 3% or less CBD (w/w).

### Claim 38 (depends on 35, 36, 37)

A preparation according to any one of claims 35 to 37 comprising less than 1%, preferably less than 0.8%, more preferably less than 0.6%, more preferably less than 0.4%, more preferably less than 0.2% or most preferably less than 0.1% Δ9 THCA (w/w).

### Claim 39 (depends on 35, 36, 37, 38)

A preparation according to any one of claims 35 to 38 comprising less than 1%, preferably less than 0.8%, more preferably less than 0.6%, more preferably less than 0.4%, more preferably less than 0.2% or most preferably less than 0.1% Δ9 THC (w/w).

### Claim 40

A substantially pure preparation of cannabidiolic acid (CBDA) having a chromatographic purity of greater than 94%, more preferably greater than 96% or most preferably greater than 98% by area normalisation of an HPLC profile.

### Claim 41 (depends on 40)

A preparation according to claim 40 which is a clear colourless solution at room temperature.

### Claim 42 (depends on 40, 41)

A preparation according to claim 40 or claim 41 comprising 3% or less, preferably 2% or less, more preferably 1%, or most preferably less than 0.1% CBD (w/w).

### Claim 43 (depends on 40, 41, 42)

A preparation according to any one of claims 40 to 42 comprising less than 0.8%, preferably less than 0.6%, more preferably less than 0.3% Δ9 THCA (w/w).

### Claim 44 (depends on 40, 41, 42, 43)

A preparation according to any one of claims 40 to 43 comprising less than 1%, preferably less than 0.8%, more preferably less than 0.6%, more preferably less than 0.4%, more preferably less than 0.2% or most preferably less than 0.1% Δ9 THC (w/w).

### Claim 45 (depends on 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

A preparation according to any one of claims 35 to 44 which is obtainable from cannabis plant material using a method comprising:
i) preparing an extract of the cannabis plant material with 0.1% v/v acetic acid in hexane,
ii) filtering the resultant extract and removing solvent from filtrate by rotary evaporation to form an extract enriched in CBDA,
iii) passing a solution of the resulting CBDA enriched extract through a column packed with Sephadex-LH20™, eluting with 2:1 chloroform/dichloromethane,
iv) collecting CBDA rich fractions eluted from the column and removing solvent by rotary evaporation,
v) re-dissolving the crude CBDA obtained in step iv) in methanol, removing insoluble residue by filtration and removing solvent from filtrate by rotary evaporation,
vi) re-dissolving the product of step v) in pentane, removing insoluble residue by filtration and removing solvent from filtrate by rotary evaporation to produce CBDA crystals.

### Claim 46

A substantially pure preparation of cannabidiolic acid (CBDA) substantially as described herein and having an HPLC profile substantially as shown in FIG. 4.

### Claim 47

A substantially pure preparation of cannabidiolic acid (CBDA) substantially as described herein and having an HPLC profile substantially as shown in FIG. 5.

### Claim 48

A substantially pure preparation of Δ9 tetrahydrocannabinol (Δ9 THC) having a chromatographic purity of >99% by area normalisation of an HPLC profile.

### Claim 49 (depends on 48)

A preparation according to claim 48 which is a semi-solid at room temperature.

### Claim 50 (depends on 48, 49)

A preparation according to claim 48 or claim 49 which comprises less 0.5%, preferably than 0.4%, more preferably less than 0.2% or most preferably less than 0.1% CBD (w/w).

### Claim 51 (depends on 48, 49, 50)

A preparation according to any one of claims 48 to 50 which comprises less than 0.5%, preferably less than 0.4%, more preferably less than 0.2% or most preferably less than 0.1% CBN (w/w).

### Claim 52 (depends on 48, 49, 50, 51)

A preparation according to any one of claims 48 to 51 which is obtainable from cannabis plant material using a method comprising:
i) obtaining an ethanolic solution of a botanical drug substance from decarboxylated cannabis plant material,
ii) passing the solution obtained in step i) through a column of activated charcoal, and collecting the eluate,
iii) remove solvent from the eluate by rotary evaporation to give a Δ9 THC enriched fraction,
iv) passing a solution of the resulting Δ9 THC enriched extract through a column packed with Sephadex LH20, eluting with 2:1 chloroform/dichloromethane,
v) collecting Δ9 THC rich fractions and removing solvent by rotary evaporation,
vi) re-dissolving the crude Δ9 THC prepared in step v) in methanol, removing insoluble residue by filtration and removing solvent from filtrate by rotary evaporation,
vii) re-dissolving the crude Δ9 THC prepared in step vi) in pentane, removing insoluble residue by filtration and removing solvent from the filtrate by rotary evaporation to give a semi-solid preparation of Δ9 THC.

### Claim 53 (depends on 52)

A preparation according to claim 52 wherein the ethanolic solution of a botanical drug substance from decarboxylated cannabis plant material is obtained by a method comprising the following steps:
i) harvesting cannabis plant material,
ii) decarboxylation of the plant material,
iii) extraction with liquid carbon dioxide (CO2), removal of CO2 to recover crude extract,
iv) dissolution of crude extract in ethanol followed by chilling of the solution to precipitate unwanted waxes,
v) removal of unwanted waxy material by cold filtration.

### Claim 54

A substantially pure preparation of Δ9 tetrahydrocannabinol (Δ9 THC) substantially as described herein and having an HPLC profile substantially as shown in FIG. 8.

### Claim 55

A substantially pure preparation of Δ9 tetrahydrocannabivarin (Δ9 THCV) having a chromatographic purity of greater than 95%, more preferable greater than 96%, more preferable greater than 97%, more preferable greater than 98%, and most preferable greater than 99% by area normalisation of an HPLC profile.

### Claim 56 (depends on 55)

A preparation according to claim 55 which is a crystalline solid at room temperature.

### Claim 57 (depends on 55, 56)

A preparation according to claim 55 or claim 56 which comprises less than 1%, preferably less than 0.8%, more preferably less than 0.6%, more preferably less than 0.4%, more preferably less than 0.2% or most preferably less than 0.1% CBD (w/w).

### Claim 58 (depends on 55, 56, 57)

A preparation according to any one of claims 55 to 57 which comprises less than 2.0%, preferably less than 1.5%, more preferably less than 1.0% or most preferably 0.5% or less Δ9 THC (w/w).

### Claim 59 (depends on 55, 56, 57, 58)

A preparation according to any one of claims 55 to 58 which comprises less than 1%, preferably less than 0.8%, more preferably less than 0.6%, more preferably less than 0.4%, more preferably less than 0.2% or most preferably less than 0.1% CBN (w/w).

### Claim 60 (depends on 55, 56, 57, 58, 59)

A preparation according to any one of claims 55 to 59 which is obtainable from cannabis plant material using a method comprising:
i) obtaining an ethanolic solution of a botanical drug substance from cannabis plant material,
ii) passing the solution obtained in step i) through a column of activated charcoal, and collecting the eluate,
iii) remove solvent from the eluate by rotary evaporation to give a Δ9 THCV enriched fraction,
iv) passing a solution of the resulting Δ9 THCV enriched extract through a column packed with Sephadex LH20, eluting with 2:1 chloroform/dichloromethane,
v) collecting Δ9 THCV rich fractions and removing solvent by rotary evaporation,
vi) re-dissolving the crude Δ9 THCV prepared in step v) in methanol, removing insoluble residue by filtration and removing solvent from filtrate by rotary evaporation,
vii) re-dissolving the crude Δ9 THCV prepared in step vi) in pentane, removing insoluble residue by filtration and removing solvent from the filtrate by rotary evaporation to give crystals of Δ9 THCV.

### Claim 61 (depends on 60)

A preparation according to claim 60 wherein the ethanolic solution of a botanical drug substance from decarboxylated cannabis plant material is obtained by a method comprising the following steps:
i) harvesting cannabis plant material,
ii) extraction with liquid carbon dioxide (CO2), removal of CO2 to recover crude extract,
iii) dissolution of crude extract in ethanol followed by chilling of the solution to precipitate unwanted waxes,
vi) removal of unwanted waxy material by cold filtration.

### Claim 62

A substantially pure preparation of Δ9 tetrahydrocannabivarin (Δ9 THCV) substantially as described herein and having an HPLC profile substantially as shown in FIG. 11.

### Claim 63

A product enriched in cannabigerol (CBG) having a chromatographic purity of greater than 90%, preferably greater than 92% by area normalisation of an HPLC profile.

### Claim 64 (depends on 63)

A product according to claim 63 which is an orange-yellow semi-solid at room temperature.

### Claim 65 (depends on 63, 64)

A product according to claim 63 or claim 64 which comprises less than 1%, preferably less than 0.8%, more preferably less than 0.6%, more preferably less than 0.4%, more preferably less than 0.2% or most preferably less than 0.1% CBD (w/w).

### Claim 66 (depends on 63, 64, 65)

A product according to any one of claims 63 to 65 which comprises less than 1%, preferably less than 0.8%, more preferably less than 0.6%, more preferably less than 0.4%, more preferably less than 0.2% or most preferably 0.1% or less Δ9 THC (w/w).

### Claim 67 (depends on 63, 64, 65, 66)

A product according to any one of claims 63 to 66 which comprises less than 1%, preferably less than 0.8%, more preferably less than 0.6%, more preferably less than 0.4%, more preferably less than 0.2% or most preferably less than 0.1% CBN (w/w).

### Claim 68

A substantially pure preparation of cannabigerol (CBG) having a chromatographic purity of greater than 92%, more preferably greater than 94%, more preferably greater than 96% or most preferably greater than 97% by area normalisation of an HPLC profile.

### Claim 69 (depends on 68)

A preparation according to claim 68 which is a clear colourless solution at room temperature.

### Claim 70 (depends on 68, 69)

A preparation according to claim 68 or claim 69 which comprises 4% or less, more preferably 3% or less, or most preferably less than 2% CBD (w/w).

### Claim 71 (depends on 68, 69, 70)

A preparation according to any one of claims 68 to 70 which comprises less than 1%, preferably less than 0.8%, more preferably less than 0.6%, more preferably less than 0.4%, more preferably less than 0.2% or most preferably less than 0.1% Δ9-THC (w/w).

### Claim 72 (depends on 68, 69, 70, 71)

A preparation according to any one of claims 68 to 71 which comprises less than 1%, preferably less than 0.8%, more preferably less than 0.6%, more preferably less than 0.4%, more preferably less than 0.2%, or most preferably less than 0.1% CBN (w/w).

### Claim 73 (depends on 63, 64, 65, 66, 67, 68, 69, 70, 71, 72)

A product according to any one of claims 63 to 72 which is obtainable from cannabis plant material using a method comprising:
i) decarboxylating the cannabis plant material,
ii) preparing an extract of the decarboxylated cannabis plant material with hexane,
iii) filtering the resultant extract and removing solvent from filtrate by rotary evaporation to form an extract enriched in CBG,
iv) passing a solution of the resulting CBG enriched extract through a column packed with Sephadex-LH20™, eluting with 2:1 chloroform/dichloromethane,
v) collecting CBG rich fractions eluted from the column and removing solvent by rotary evaporation,
vi) re-dissolving the crude CBG obtained in step v) in methanol, removing insoluble residue by filtration and removing solvent from filtrate by rotary evaporation,
vii) re-dissolving the product of step vi) in pentane, removing insoluble residue by filtration and removing solvent from filtrate by rotary evaporation to produce a highly enriched CBG extract or substantially pure cannabigerol.

### Claim 74 (depends on 73)

A product according to claim 73 wherein the method includes a further step viii) of loading the highly enriched CBG extract or substantially pure cannabigerol onto a Chromabond Flash BT 12M silica cartridge column, and eluting with hexane:ethyl:acetate (98:2) at a flow rate of approximately 5 ml/min.

### Claim 75

A product enriched in cannabigerol (CBG) substantially as described herein and having an HPLC profile substantially as shown in FIG. 14.

### Claim 76

A substantially pure preparation of cannabigerol (CBG) substantially as described herein and having an HPLC profile substantially as shown in FIG. 15.

### Claim 77

A substantially pure preparation of cannabigerol (CBG) substantially as described herein and having an HPLC profile substantially as shown in FIG. 16.

### Claim 78

A product enriched in cannabichromene (CBC) having a chromatographic purity of greater than 80%, more preferably greater than 85% by area normalisation of an HPLC profile.

### Claim 79 (depends on 78)

A product according to claim 78 which is an orange-yellow semi-solid at room temperature.

### Claim 80 (depends on 78, 79)

A product according to claim 78 or claim 79 which comprises less than 5%, preferably less than 4%, more preferably less than 3%, more preferably less than 2% or most preferably 1% or less CBD (w/w).

### Claim 81 (depends on 78, 79, 80)

A product according to any one of claims 78 to 80 which comprises less than 2%, preferably less than 1.5%, more preferably less than 1.0%, more preferably less than 0.5% or most preferably 0.3% or less Δ9 THC (w/w).

### Claim 82 (depends on 78, 79, 80, 81)

A product according to any one of claims 78 to 81 which comprises less than 1%, preferably less than 0.8%, more preferably less than 0.6%, more preferably less than 0.4%, more preferably less than 0.2% or most preferably 0.1% or less CBN (w/w).

### Claim 83

A substantially pure preparation of cannabichromene (CBC) having a chromatographic purity of greater than 85%, more preferably greater than 90%, more preferably greater than 95%, more preferably greater than 98% or most preferably greater than 99% by area normalisation of an HPLC profile.

### Claim 84 (depends on 83)

A preparation according to claim 83 which is a clear colourless solution at room temperature.

### Claim 85 (depends on 83, 84)

A preparation according to claim 83 or claim 84 which comprises 1% or less, more preferably 0.8% or less, more preferably 0.6% or less, more preferably 0.4% or less or most preferably less than 0.2% CBD (w/w).

### Claim 86 (depends on 83, 84, 85)

A preparation according to any one of claims 83 to 85 which comprises less than 1%, preferably less than 0.8%, more preferably less than 0.6%, more preferably less than 0.4%, more preferably less than 0.2% or most preferably less than 0.1% Δ9-THC (w/w),

### Claim 87 (depends on 83, 84, 85, 86)

A preparation according to any one of claims 83 to 86 less than 1%, preferably less than 0.8%, more preferably less than 0.6%, more preferably less than 0.4%, more preferably less than 0.2% or most preferably less than 0.1% CBN (w/w).

### Claim 88 (depends on 78, 79, 80, 81, 82, 83, 84, 85, 86, 87)

A product according to any one of claims 78 to 87 which is obtainable from cannabis plant material using a method comprising:
i) decarboxylating the cannabis plant material,
ii) preparing an extract of the decarboxylated cannabis plant material with hexane,
iii) filtering the resultant extract and removing solvent from filtrate by rotary evaporation to form an extract enriched in CBC,
iv) passing a solution of the resulting CBC enriched extract through a column packed with Sephadex-LH20™, eluting with 2:1 chloroform/dichloromethane,
v) collecting CBC rich fractions eluted from the column and removing solvent by rotary evaporation,
vi) re-dissolving the crude CBC obtained in step v) in methanol, removing insoluble residue by filtration and removing solvent from filtrate by rotary evaporation,
vii) re-dissolving the product of step vi) in pentane, removing insoluble residue by filtration and removing solvent from filtrate by rotary evaporation to produce a highly enriched CBC extract.

### Claim 89

A product enriched in cannabichromene (CBC) substantially as described herein and having an HPLC profile substantially as shown in FIG. 19.

### Claim 90

A substantially pure preparation of cannabichromene (CBC) substantially as described herein and having an HPLC profile substantially as shown in FIG. 20.

### Claim 91 (depends on 1)

A method according to claim 1 which comprises a further step v) of:
v) loading the substantially pure cannabinoid or cannabinoid acid or the product enriched in a given cannabinoid or cannabinoid acid onto a Chromabond Flash BT 12M silica cartridge column, eluting with hexane:ethyl acetate (98:2) at a flow rate of approximately 5 ml/min.
